Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Remedium Lifecare Limited is a pharmaceutical company specializing in trading and selling APIs and intermediates. They operate in both domestic and international markets, including regulated ones.
The company changed its name from 'Roxy Exports Limited' to 'Remedium Lifecare Limited' to reflect its updated business focus.
In 2021, Remedium Lifecare transitioned from manufacturing Air-O-Water machines to trading API intermediates and contract manufacturing, indicating a strategic realignment.
Remedium Lifecare emphasizes innovation in the pharmaceutical industry, focusing on trading advanced intermediates vital for API manufacturing.
Its history dates back to 1988, positioning it as an experienced entity in the evolving pharmaceutical sector.
Commercial Services & Supplies
Trading & Distributors
39 Cr
Low Risk
7.8
21.6
0.6
0.4
1.94
0.32
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
69.50 | 41 Cr | -82.76 | 0.48 | 0.00 | 3.28 | 32.04 | 31.59 | ||
0.19 | 39 Cr | 1.72 | 0.19 | 0.00 | 3.61 | 2.38 | 2.33 | ||
0.39 | 39 Cr | 7.80 | 0.42 | 0.00 | 0.00 | 0.00 | — | ||
39.70 | 39 Cr | 5.33 | 1.27 | 0.00 | 14.85 | 16.62 | 8.02 | ||
13.52 | 38 Cr | 16.90 | 2.54 | 0.00 | 5.35 | 5.60 | 6.59 | ||
0.47 | 37 Cr | 0.06 | 0.32 | 0.00 | 1.72 | 3.38 | -7.35 | ||
65.59 | 36 Cr | 5.38 | 0.68 | 0.00 | 11.59 | 11.79 | 3.11 | ||
| Median: 7 Co. | — | 13.52 | 39 Cr | 5.33 | 0.48 | 0.00 | 3.61 | 5.60 | 4.85 |
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Remedium Lifecare Ltd (REMLIFE) is currently trading at 0.46 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Remedium Lifecare Limited is a pharmaceutical company specializing in trading and selling APIs and intermediates. They operate in both domestic and international markets, including regulated ones. The company changed its name from 'Roxy Exports Limited' to 'Remedium Lifecare Limited' to reflect its updated business focus. In 2021, Remedium Lifecare transitioned from manufacturing Air-O-Water machines to trading API intermediates and contract manufacturing, indicating a strategic realignment. Remedium Lifecare emphasizes innovation in the pharmaceutical industry, focusing on trading advanced intermediates vital for API manufacturing. Its history dates back to 1988, positioning it as an experienced entity in the evolving pharmaceutical sector.
Over the past 52 weeks, Remedium Lifecare Ltd has traded between a low of ₹0.32 and a high of ₹1.94. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Remedium Lifecare Ltd has a market capitalization of approximately 38.81. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Remedium Lifecare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 7.80 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 38.81 Cr, Remedium Lifecare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Remedium Lifecare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Remedium Lifecare Ltd is 7.80. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The company disclosed that MCA approved the name change from Remedium Lifecare Ltd. to Supha Pharmachem Limited, effective 15/12/2025.
Supha Pharmachem, formerly Remedium Lifecare, was admitted into the Corporate Insolvency Resolution Process (CIRP) by the NCLT after it defaulted on a payment of ₹7.47 crore to an operational creditor, Boston Ivy Healthcare Solution Private Limited.
Supha Pharmachem entered the Corporate Insolvency Resolution Process (CIRP) after the NCLT admitted a petition from Boston Ivy Healthcare Solution Private Limited due to a payment default of Rs. 7,47,20,079.
The most significant announcement is the 'Biopharma Shakti' initiative, a ₹10,000 crore program designed to boost domestic manufacturing of biologics and biosimilars, which is expected to increase demand for API intermediates traded by the company.
Bearish
8
Neutral
1
Bullish
5
Bearish
22
Neutral
1
Bullish
23
Bearish
14
Neutral
0
Bullish
18
CIRP/CoC Outcome
First CoC meeting (14 Apr 2026; e‑voting closed 16 Apr) ratified IRP remuneration/expenses, approved appointment of Raju M. Marshiya as Resolution Professional (another nominee rejected), approved legal fees, bank operations and 6‑month budget; directors non‑cooperative.
CoC Meeting Outcome
1st Committee of Creditors (14 Apr 2026) approved IRP remuneration/CIRP expenses, appointed Raju Mangilal Marshiya as Resolution Professional, approved legal advisor fees, bank operations and 6-month budget; rejected Rishab Sethi and two valuers; directors non-cooperative.
